The OpenAI verdict is a green light for the most anticipated tech IPO in years.

A jury in Oakland ruled unanimously against Elon Musk on Monday, finding that his claims against OpenAI and CEO Sam Altman were time-barred under the statute of limitations. The decision came after a three-week trial and less than two hours of deliberation, and Musk's attorney acknowledged the fight continues, saying the "war" is "not over" and signaling an appeal.

But appeals take time, and OpenAI now has a clean runway. The lawsuit had been the single most disruptive legal cloud over the company's IPO planning, and a unanimous jury finding - not a close call - gives underwriters and institutional buyers the clarity they needed. Musk's appeal threat is real, but it no longer blocks the process.

Lilly's Supreme Court loss is a warning shot for every pharma company on Medicaid pricing.

The U.S. Supreme Court declined Monday to hear Eli Lilly's appeal of a $194 million whistleblower judgment tied to allegations that the company misreported drug pricing data to underpay Medicaid rebates. More consequentially, the Court also rejected Lilly's challenge to the False Claims Act whistleblower framework itself, leaving that Civil War-era law fully intact. LLY shares fell 1.66% on the day.

The refusal to touch the False Claims Act is the bigger story. Lilly was not just fighting one verdict - it was trying to narrow the legal exposure that every large pharmaceutical company carries on government pricing compliance. That door is now closed, and the next whistleblower case in the sector starts from a stronger legal foundation than it did last week.

Takeda's $885 million antitrust verdict exposes the real cost of pay-for-delay tactics.

A U.S. jury found Monday that Takeda ran an anticompetitive scheme to block generic versions of its constipation drug Amitiza from reaching the market, awarding roughly $885 million to pharmacies, insurers, and retailers harmed by the conduct. TAK shares barely moved, down just 0.18%, suggesting the market had partially priced in the risk. The company is simultaneously running a transformation program targeting over $1.3 billion in annualized gross savings by FY2028.

The muted stock reaction should not obscure the strategic damage. Takeda is trying to reposition around a pipeline that includes oveporexton, rusfertide, and zasocitinib - a forward-looking story that requires investor trust in management's judgment. A jury finding of deliberate anticompetitive conduct is exactly the kind of headline that complicates that narrative, regardless of whether the savings program ultimately delivers.